{"id":11726,"date":"2003-10-01T11:11:46","date_gmt":"2003-10-01T11:11:46","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=11726"},"modified":"2014-05-27T11:06:59","modified_gmt":"2014-05-27T11:06:59","slug":"cdc-study-shows-rifampinpyrazinamide-therapy-can-cause-severe-liver-damage","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/11726","title":{"rendered":"CDC study shows rifampin\/pyrazinamide therapy can cause severe liver damage"},"content":{"rendered":"<p><strong>Graham McKerrow, HIV i-Base<\/strong><\/p>\n<p><strong>Treatment of latent TB with a two-month therapy regimen of rifampin and pyrazinamide (RZ) can cause severe liver damage and even death, according to a study by the US Centers for Disease Control and Prevention (CDC).<\/strong><\/p>\n<p>The CDC has previously reported surveillance data of severe liver damage in patients treated with a daily and twice-weekly two-month regimen of RZ. To estimate the incidence of severe liver damage they collected data on patients in the United States who received treatment between January 2000 and June 2002. [1] CDC found reports of 48 latent TB patients with confirmed cases of severe liver injury after receiving the treatment. Eleven patients died. As a result the American Thoracic Society and CDC now recommend that this regimen should not normally be offered to people with latent TB.<\/p>\n<p>The agency recommends a nine-month regimen of isoniazid as the preferred treatment for latent TB. [2] It also says that rifampin and pyrazinamide should continue to be used in multidrug regimens for the treatment of active TB disease.<\/p>\n<p>Ref: Centers for Disease Control and Prevention (CDC); American Thoracic Society. Update: adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection &#8211; United States, 2003. MMWR Morb Mortal Wkly Rep. 2003 Aug 8;52(31):735-9.<\/p>\n<p>CDC summary:<br \/>\n<a href=\"http:\/\/www.cdc.gov\/nchstp\/tb\/pubs\/tbfactsheets\/250110.htm\">http:\/\/www.cdc.gov\/nchstp\/tb\/pubs\/tbfactsheets\/250110.htm<\/a><\/p>\n<p>References:<\/p>\n<ol>\n<li>DC. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society\/CDC recommendations \u2013 United States, 2001. MMWR 2001;50 (No.34).<br \/>\n<a href=\"http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm5034a1.htm\">http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm5034a1.htm<\/a><\/li>\n<li>2. CDC. Update: Adverse Event Data and Revised American Thoracic Society\/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection. MMWR 2003; 52 (No. 31).<br \/>\n<a href=\"http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm5231a4.htm\">http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm5231a4.htm<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Graham McKerrow, HIV i-Base Treatment of latent TB with a two-month therapy regimen of rifampin and pyrazinamide (RZ) can cause severe liver damage and even death, according to a study by the US Centers for Disease Control and Prevention (CDC). &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[],"class_list":["post-11726","post","type-post","status-publish","format-standard","hentry","category-tb-coinfection"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/11726","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=11726"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/11726\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=11726"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=11726"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=11726"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}